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Abstract Tumor cells use several mechanisms such as solu­
ble immune modulators or suppressive immune cells to evade 
from anti-tumor responses. Immunomodulatory cytokines, 
such as transforming growth factor-β, interleukin (IL)-10, 
and IL-35, soluble factors, such as adenosine, immunosup­
pressive cells, such as regulatory T cells, NKT cells and 
myeloid-derived suppressor cells (MDSCs), are the main or­
chestra leaders involved in immune suppression in cancer by 
which tumor cells can freely expand without immune cell-
mediated interference. Among them, MDSCs have attracted 
much attention as they represent a heterogenous population 
derived from myeloid progenitors that are expanded in tumor 
condition and can also shift toward other myeloid cells, such 
as macrophages and dendritic cells, after tumor clearing. 
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MDSCs exert their immunosuppressive effects through vari­
ous immune and non-immune mechanisms which make them 
as potent tumor-promoting cells. Although, there are several 
studies regarding the immunobiology of MDSCs in different 
solid tumors, little is known about the precise characteristics 
of these cells in hematological malignancies, particularly B 
cell malignancies. In this review, we tried to clarify the precise 
role of MDSCs in B cell-derived malignancies. 
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Introduction 
Tumor cells escape from anti-tumor immune responses in part 
through induction of immunosuppressive microenvironment 
in which immune cells cannot eradicate tumor cells. Several 
immunosuppressive mechanisms are involved in tumor-
induced suppression, including soluble factors and immuno­
suppressive cells. Soluble immunosuppressive factors such as 
transforming growth factor (TGF)-β, interleukin (IL)-10, IL­
35, adenosine, and hypoxy inducible factor (HIF) can enhance 
tumor growth through inhibition of anti-tumor responses 
[1–3]. There are also various immunosuppressive cells such 
as regulatory T (Treg) cells [4], type II natural killer T (NKT 
II) [5], tumor-associated macrophages [6], and myeloid­
derived suppressor cells (MDSCs) [7] that can help to tumor 
escape process. In the most common types of the cancers, the 
combination of these immunosuppressive factors contributes 
to inhibition of anti-tumor responses. However, MDSCs have 
attracted the high attention in recent years due to their com­
plex immunobiology in various cancer and autoimmune dis­
eases [8]. 
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MDSCs are a heterogeneous population of cells derived 
from myeloid progenitor cells and immature myeloid cells. 
MDSCs were initially identified as natural suppressor cells 
in tumor-bearing mice about three decades ago [9]. While 
the murine-derived MDSCs are characterized by the expres­
sion of Gr-1 and CD11b molecules, the human MDSCs ex­
hibit CD33+HLA-DRlow/− phenotype. It has been shown that 
MDSCs exert their immunosuppressive function through var­
ious mechanisms such as the production of reactive oxygen 
species (ROS), nitric oxide (NO), arginase, and cytokines 
[10]. Several studies have investigated the role of MDSCs in 
different solid tumors; however, little is known regarding the 
immunobiology of these cells in B cell malignancies [11, 12]. 
Therefore, we reviewed studies related to the role of MDSCs 
in various B cell-derived malignancies in order to enlarge and 
clarify the precise function of these cells in B cell cancers. 
Myeloid-derived suppressor cells 
MDSCs are a heterogeneous population derived from the my­
eloid cell lineage. Bone marrow-derived immature myeloid 
cells usually differentiate into myeloid cell lineage including 
mature granulocytes, macrophages, or dendritic cells (DCs); 
however, in some pathological conditions such as cancer, a 
partial block of their differentiation leads to development of 
MDSCs. These pathologically expanded cells are not a dis­
criminated subtype of myeloid cells but rather a complex het­
erogeneous population of activated immature myeloid cells 
that their development into mature cells is inhibited [13]. It 
is now evident that MDSCs are not solely the consequent of 
myeloid precursor cells development during long-term patho­
logical situation. MDSC term is the functional description of 
immature myeloid cells that have earned various immunosup­
pressive properties [14]. 
MDSC population contains a mixture of myeloid cells 
with granulocytic and monocytic phenotype. MDSCs in 
mice are characterized by the expression of Gr1 (Ly6G) 
and CD11b (αM-integrin) molecules, that constitute about 
the 20–30 % of the normal bone marrow cells and 2–4 % of  
spleen cells and are absent from the lymph nodes. MDSCs 
in humans are usually characterized by the CD14−CD11b+ 
phenotype; however, they can also be defined as CD33+ 
(common myeloid marker) HLA-DR− cells that do not ex­
press markers of mature myeloid and lymphoid cells. Re­
cently, it is suggested that CD15 and CD66b molecules 
may discriminate granulocytic and monocytic MDSCs 
(G-MDSC and M-MDSC) in peripheral blood of humans 
[15]. In mice, a Gr-1high MDSCs are mainly granulocytic; 
however, a Gr-1int cells contain M-MDSCs [16, 17]. As 
anti-Gr-1 monoclonal antibody binds to two molecules belong­
ing to the Ly6 superfamily, Ly6G and Ly6C, the use of this 
antibody could not precisely discriminate MDSCs subsets [18, 
19]. G-MDSCs exhibit CD11b+Ly6G+Ly6Clow high SSC 
phenotype; however, M-MDSCs have CD11b+Ly6G−Ly6Chigh 
low SSC morphology. M-MDSCs express higher levels of F4/ 
80, CD115, 7/4, and CCR2molecules compared to G-MDSCs, 
at least in some tumor models [20]. Discrimination of these two 
subsets is important as they exert different functions in patho­
logic conditions such as cancer. For example, it is suggested 
that G-MDSCs have higher capacity for expansion in animal 
tumor models and use different immunosuppressive mecha­
nisms, whereas only M-MDSCs can differentiate into mature 
DCs and macrophages, in vitro [15, 21]. Other surface mole­
cules such as CD80 (B7.1), CD115 (macrophage colony­
stimulating factor receptor), and CD124 (IL-4 receptor α) have  
also been suggested in order to classify MDSCs to further 
subsets [15]. However, it is demonstrated that these markers 
cannot characterize specific subset of MDSCs in several tumor 
models [21]. As G-MDSCs exert their immunosuppressive 
effects mainly through ROS, it seems they use cell contact-
dependent mechanisms, which implies antigen-specific 
interaction between MDSC and Tcells [22]. On the other hand, 
M-MDSCs inhibit anti-tumor responses usually through NO, 
arginase, and cytokines which rely on cell contact-independent 
mechanisms and target antigen-independent T cell responses 
[23]. Although G-MDSCs are more prevalent in peripheral 
lymphoid organs in many tumor models [21], it is generally 
proposed that M-MDSCs exhibit higher immunosuppressive 
effects compared to G-MDSC in tumor microenvironment 
[24, 25]. This is consistent with what observed regarding the 
antigen-specific tolerance of T cells in peripheral lymphoid 
organs in most tumors and their ability to respond to non­
specific stimuli [26]. However, it should be noted that the ratio 
of G-MDSC to M-MDSC in various experimental models can 
be highly variable and depends on several factors in tumor 
microenvironment and peripheral [25]. 
As the cells with the abovementioned phenotypes do not 
exhibit the functional characteristics of MDSCs in normal 
humans and mice, it seems that these cells do not really exist 
in healthy non-pathologic conditions, and we propose to call 
them as MDSC-like or non-MDSC immature myeloid cells. 
Thus, MDSCs develop only during time-consuming untreated 
pathological conditions such as chronic inflammatory infec­
tious diseases or cancer. 
It is demonstrated that several biologic factors affect the 
development, expansion, and activation of MDSCs, such 
as cytokines, toll-like receptor ligands, and complement 
proteins. These factors are mainly supplied by T cells, tu­
mor cells, and tumor stroma. These factors altogether en­
hance the signaling pathways that induce the set of MDSC­
promoting transcription factors including signal transducer 
and activator of transcription (STAT)3, STAT1, STAT6, 
and nuclear factor (NF)-κB [27]. 
Several factors such as cyclooxygenase-2 (COX2), prosta­
glandins, macrophage colony-stimulating factor (M-CSF), 
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granulocyte/macrophage colony-stimulating factor (GM­
CSF), G-CSF, vascular endothelial growth factor (VEGF), 
and interferon (IFN)-γ can affect the expansion and function 
of MDSCs [28]. 
Activation of COX pathway in tumor cells leads to upreg­
ulation of PGE2 which is involved in inflammatory processes 
and supports tumorigenesis. PGE2 can also recruit MDSCs 
into tumor region and promote myeloid cell differentiation 
toward MDSC, which then enhances tumor growth [29]. 
Ligation of PGE2 receptor E-prostanoid (EP) 4 in MDSCs 
could upregulate arginase 1 expression [30]. Furthermore, 
stimulation of EP receptor agonists with PGE2 promoted the 
generation of MDSC from bone marrow stem cells [31]. There 
is evidence which implies that PGE2 affects the expression of 
arginase 1and NOS2 [32]. 
It is demonstrated that high levels of M-CSF inhibit the 
proper myeloid development, leading to expansion of MDSCs. 
Moreover, upregulation of M-CSF in pathological conditions 
was associated with expansion of MDSCs [33]. Migration of 
macrophages to inflammatory tissues was also associated with 
increased levels of M-CSF that contributes to expansion of 
MDSCs [34]. However, it is a matter of debate that whether 
MDSCs express M-CSF receptor or not. Administration of 
anti-M-CSF receptor monoclonal antibody to mice prevented 
the infiltration of M-MDSCs in lung and prostate tumors [35]. 
GM-CSF promotes antigen presentation by DCs and 
increases T cell responses at low concentrations [36]. In 
contrast, high concentration of GM-CSF is associated 
with downregulation of DC differentiation and expansion 
of CD11b+Gr-1+ MDSCs [37]. Cancer cells can produce 
GM-CSF that enhances the induction and expansion of 
MDSCs in secondary lymphoid organs and at the tumor 
region [38]. Treatment of mice with recombinant GM­
CSF substantiated the stimulatory effect of this factor on 
MDSCs [39]. Concentration of GM-CSF and length of 
stimulation are two important factors that assign the im­
mune stimulatory or immune suppressive effects of this 
factor on immune responses. GM-CSF may also affect 
differentially on development of various MDSC subsets. 
While it induces both CD11b+Gr-1int and CD11b+Gr-1low 
subtypes in the spleen of tumor-bearing mice, it enhanced 
only the CD11b subset in the bone marrow [24]. 
G-CSF promotes the expansion of MDSCs in tumor 
models, which is in part through the upregulation of var­
ious cytokines and transcription factors that enhance 
MDSC expansion [40]. It has also been demonstrated that 
MDSC-inducing cytokines such as IL-1 and IL-17 can 
also stimulate G-CSF generation [41, 42]. Moreover, up­
regulation of G-CSF responsive genes, including PU.1 
and C/EBPβ, was associated with MDSC expansion [43, 
44]. Furthermore, signaling of G-CSFR leads to activation 
of STAT3 [45] which is the main MDSC-inducing tran­
scription factor [46]. There is also evidence which implies 
the stimulatory effect of G-CSF on the expansion of G-
MDSCs in tumor models [47]. There are also other stud­
ies that show MDSCs can upregulate MDSC-inducing 
signaling pathways such as Jak/Stat pathway [48]. Thus, 
it seems that the high concentrations of G-CSF can ex­
pand MDSCs. 
Ligation of VEGFR1 improves the generation of Gr-1+ 
myeloid cells [49]. Signaling of VEGFR2 also induces 
CD11b+Gr-1+ MDSCs accompanied with the expansion of 
B cells at the pro-B cell stage [50]. Continuous signaling 
through VEGF inhibits NF-κB and FLT3L signals which lead 
to expansion of immature myeloid cells [51]. Stimulation of 
MDSCs by exogenous or autocrine IFN-γ also leads to up-
regulation of arginase1, inducible nitric oxide synthase 
(iNOS), and IL-13 in these cells, and induces the expression 
of IL-4 and IL-13 receptors [16].While the blockade of IFN-γ
secretion inhibited MDSC-induced T cell suppression [16], 
the synergistic function of IFN-γ produced by T cells and 
MDSCs increases the immunosuppressive effect of MDSCs 
in both STAT1-dependent and STAT1-independent manners 
[52]. It is suggested that IFN-γ promotes the generation of 
MDSCs in part through the activation of interferon regulatory 
factor-8 (IRF-8) [53]. 
To lesser extent compared to the abovementioned factors, 
other biologic materials, such as TGF-β, stem cell factor 
(SCF), IL-1β, IL-6, IL-4, IL-10, IL-12, IL-13, and matrix 
metalloprotease-9 (MMP-9), can also affect the expansion 
and function of MDSCs [54]. 
Most of the abovementioned factors use Janus kinase 
(JAK) and STAT signaling molecules that mainly contribute 
to cell survival, proliferation, differentiation, and apoptosis. 
Among the STAT molecules, STAT3 exerts the highest effect 
on the induction, expansion, activation, and suppressive func­
tion ofMDSCs. Tumor-derived factors can activate JAK2 and 
STAT3 signaling molecules which were associated with ex­
pansion ofMDSCs, in vitro [55]. STAT3 was also upregulated 
in MDSCs isolated from tumor-bearing mice [56]. Inhibition 
of STAT3 also led to downregulation of MDSCs which was 
associated with augmented T cell responses in mice tumor 
models [57]. It is suggested that STAT3 promotes the devel­
opment of MDSCs in part through some downstream mole­
cules such as calcium-binding pro-inflammatory proteins 
S100A9 and S100A8 [58], and Nox2 transcription factor 
[59] which prevent DC differentiation and enhance MDSC 
expansion and activation [60]. STAT3 can also affect the de­
velopment and function of MDSCs by downregulation of pro­
tein kinase (PK) CβII [61], upregulation of CCAAT-enhancer­
binding protein beta (C/EBPβ) [62], and modulation of acute­
phase proteins [63]. Thus, it seems that continuous activation 
of STAT3 in myeloid progenitors under pathological condi­
tion leads to induction and expansion of MDSCs. 
STAT1 is another effective signaling molecule in the acti­
vation and suppressive function of MDSCs. IFN-γ and IL-1β
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can activate STAT1, which then induces iNOS and arginase 
enzymes inMDSCs [64]. It is suggested that STAT1 signaling 
has higher effects on the function of M-MDSCs compared to 
G-MDSCs [52]. Moreover, STAT5 can also modulate the sur­
vival ofMDSCs. This claimwas resulted from the study of the 
effect of sunitinib on the survival of MDSCs isolated from 
spleen and tumor of mice and humans [65]. 
Ligation of CD124 (IL-4Rα) on the MDSCs with IL-4 
or IL-13 leads to activation of STAT6 signaling, which 
then activates arginase [66] and upregulates TGF-β gen­
eration [67]. There is another evidence which implies the 
role of STAT6 signaling in the accumulation of MDSCs 
[68]. There is also a synergism between STAT1 (induced 
by IFN-γ) and STAT6 (induced by ligation of CD124) 
signaling pathways for promotion of MDSC suppressive 
functions [16]. 
Activation of NF-κB transcription factor following expo­
sure to infectious microorganisms can expand MDSCs [69]. 
Ligation of TLRs or signaling of IL-1 or IL-18 cytokines 
trigger NF-κB signaling in Myd88-dependent manner. Ac­
cordingly, treatment of mice with IL-1 receptor antagonist 
prevented gastric cancer which was associated with downreg­
ulation of MDSCs [70]. Moreover, administration of tumor 
exosomes to mice led to increased tumor metastasis in the 
lung accompanied with MDSC accumulation [71]. Thus, it 
seems that microbial-associated cancers may enhance recruit­
ment and expansion of MDSCs in part through the activation 
of NF-κB signaling by TLR ligands or IL-1 and IL-18 
cytokines. 
In spite of controversial reports, it seems that Notch signal­
ing pathway can also promote the induction and expansion of 
MDSCs [72]. There are also other signaling pathways such as 
Ras, PI3K, and TGF-β that can affect the development of 
MDSCs [27, 73]. 
MDSC can promote tumor growth by enhancing angiogen­
esis and suppression of anti-tumor responses. These cells 
stimulate angiogenesis process in part through the secretion 
of MMP and VEGF factors [74]. MDSCs can affect on both 
the innate and adaptive immune responses; however, their role 
in the suppression of T cell responses is better understood 
compared to other cells. Among the innate immune cells, 
MDSCs suppress NK cell cytotoxicity, promote the differen­
tiation of M2 macrophages, and confine the priming capacity 
of mature DCs [75]. 
MDSCs suppress T cell responses through both contact-
dependent or contact-independent and antigen-specific or 
non-specific mechanisms. There are various suppressive 
mechanisms, including induction of apoptosis [76], secretion 
of immunomodulatory factors (e.g., H2O2, TNF-α, NO, 
TGF-β) [77, 78], modulation of amino acid (tryptophan, argi­
nine, and cysteine) metabolism [79], induction of Treg cells 
[80], and restriction of T cell homing [81], by which MDSCs 
exert their immunosuppressive function (Fig. 1). 
MDSCs hydrolyze L-arginine to urea and L-ornithine by 
arginase enzymes (ARG1 and ARG2) and the iNOS2. L-orni­
thine is one of the main factors for the generation of cell cycle-
promoting polyamines that enhances the proliferation of tu­
mor cells [82]. Accordingly, there are several studies that im­
ply the upregulation of arginase function in various cancers 
[83, 84]. Catabolism of L-arginine by MDSCs leads to de­
creased availability of this cytokine from the microenviron­
ment, which then results in decreased proliferation and cyto­
kine production by T cells [85]. The lack of L-arginine affects 
Tcells in part through downregulation of CD3ζ chain [86] and  
cyclin D3 and cyclin-dependent kinase 4 (CDK4) that are the 
cell cycle regulators [87]. Moreover, NO exerts its immuno­
suppressive function through mechanisms such as the preven­
tion of JAK3 and STAT5 and induction of apoptosis [88] in T  
cells, and downregulation of MHC class II [89]. Competition 
for cysteine is another way by which MDSCs suppress T cell 
activation [79]. As T cells have none of the cysteine sup­
plying tools including cystathionase (for conversion of me­
thionine to cysteine) or the xCT chain of the xc-transporter 
(for importing cysteine) [90, 91], so they cannot provide 
cystine for themselves, leading to complete dependence to 
use of ASC neutral amino acid plasma membrane trans­
porter. On the other hand, although MDSCs can import 
cystine, however, they cannot convert it to methionine or 
cysteine because they lack cystathionase.  Similarly,  
MDSCs lack ASC neutral amino acid transporter, so they 
only import cystine without exporting cysteine, which 
leads to competition for cysteine [79]. Thus, MDSCs se­
quester cystine and deprive T cells from cysteine. It has 
also been shown that MDSCs express the tryptophan­
degrading enzyme indoleamine 2,3-dioxygenase (IDO) 
which can inhibit anti-tumor responses and help to tumor 
growth [80]. 
Production of reactive oxygen and nitrogen species is an­
other mechanism through which MDSCs inhibit anti-tumor 
responses. Several studies have been reported that the gener­
ation of ROS significantly increased by MDSCs in various 
cancers [92]. Production of ROS is one of the main immuno­
suppressive mechanisms of MDSCs, as demonstrated 
blocking ROS generation leads to defective suppressive action 
of MDSCs in mice and humans, in vitro [93]. 
Arginase and iNOS are concomitantly modulated by 
Th1 and Th2 cytokines and can synergistically suppress 
antigen-specific T cell responses. Synergistic function of 
these enzymes leads to generation of reactive nitrogen ox­
ide species (peroxynitrites) by NOS2 under limited L-argi­
nine availability situation [94], which induces apoptosis in 
antigen-specific T cells via inhibition of tyrosine phosphor­
ylation of essential proteins required for T cell activation 
such as TCR and CD8 [95]. Interestingly, this function of 
MDSCs through  peroxynitrites  affects  only TCR­
expressing T cells which contact with the peptide presented 
7343 Tumor Biol. (2015) 36:7339–7353 
Fig. 1 MDSCs exert their immunosuppressive functions through various 
mechanisms such as secretion of immunomodulatory factors (e.g., H2O2, 
TNF-α, NO, TGF-β), modulation of amino acids metabolism, induction 
of Treg cells, and restriction of T cell homing. In the tumor region, M-
MDSCs  a re  dominant  subse t  o f  MDSCs  which  p rovide  
immunosuppressive microenvironment for malignant cells, whereas G-
MDSCs are the main subset of MDSCs in peripheral. MDSCs inhibit 
by MDSCs. MDSC-derived peroxynitrites disrupt the con­
formational structure of TCR-CD3 complex which leads to 
defected T cell response to antigen stimulation [96]. 
It has also been shown that MDSCs can promote the 
differentiation and expansion of Treg cells through differ­
ent mechanisms such as production of Treg-promoting cy­
tokines or antigen presentation and cell contact-dependent 
mechanisms [80]. In contrast, it is reported that MDSCs 
inhibit the generation of Treg cells by repressing TGFβ1 
[97]. 
MDSCs may deprive naïve T cells from tumor antigens 
through inhibition of their homing into lymph nodes. It is 
suggested that MDSCs prevent the migration of T cells into 
lymph nodes in part through the downregulation of L-selectin 
on their surface [81]. 
The fate of MDSCs after tumor eradication is another in­
teresting field in which there are several unanswered ques­
tions. As MDSCs can differentiate to macrophages or DCs 
in some culture conditions [98] andMDSCs disappear follow­
ing tumor eradication by surgery [15], it is suggested that 
MDSCs shift toward some myeloid cells following tumor 
elimination which may be in part due to modification of tumor 
immunosuppressive microenvironment to normal circum­
stance. However, this field deserves further investigations as 
macrophages, DCs, and NK cells through cytokines such as IL-10 and 
TGF-β. On the other hand, they suppress T cells by arginase and iNOS 
mechanisms. DCs dendritic cells, NK natural killer cells, STAT signal 
transducer and activator of transcription, MDSC Myeloid-derived 
suppressor cell, iNOS inducible nitric oxide synthase, NO nitric oxide, 
IDO indoleamine-2,3-dioxygenase, ROS reactive oxygen species, TCR T 
cell receptor, IL interleukin 
it may also be possible that MDSCs fall into apoptosis process 
after their growth factors starvation. 
MDSCs in B cell malignancies 
Multiple myeloma 
Multiple myeloma (MM) is a B cell-derived malignancy 
which is characterized by the expansion of proliferating 
plasma cells  within the bone marrow (BM) and the 
accumulation of monoclonal antibodies in the peripheral 
blood [99]. 
5T2 and 5T33MM derived from elderly C57BL/KaLwRij 
mice are two most prevalent mouse models for in vivo study 
of MM [100]. Using these animal models, Van Valckenborgh 
and colleagues have shown that there is a significant shift 
toward M-MDSCs (CD11b+Ly6Glow) in the BM of 5T2 and 
5T33MM mice at the end stage of the disease. M-MDSCs 
could also be subdivided to various subsets based on Ly6C 
exp re s s ion  i nc lud ing in f l ammato ry  monocy te s  
(Ly6ChighSSClow), eosinophils (Ly6Cint SSChigh), and imma­
ture myeloid cells (Ly6CintSSClow). Among them, inflamma­
tory monocytes exert the highest immunosuppression. They 
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demonstrated that the frequency of immature myeloid cells is 
markedly increased in the BM of MM mice models, which 
implies a differentiation block in the development of myeloid 
cells. Moreover, M-MDSCs had higher capacity for suppres­
sion of T cells compared to G-MDSCs. Myeloma-derived 
MDSCs also expressed higher levels of inhibitory molecules 
such as iNOS, arginase-1, and IL-10, compared to naïve mice 
MDSCs. They suggested that MDSCs exert their immunosup­
pressive function in part through iNOS, as inhibition of iNOS 
by l-NMMA led to attenuation of MDSC inhibitory effects on 
T cell proliferation [101]. Using 5TGM1 model, it has been 
shown that MDSCs accumulate in the blood, BM, and spleen 
over time following 5TGM1-GFP myeloma cells inoculation. 
Moreover, these tumor-induced MDSCs could differentiate 
into mature and functional osteoclasts both in vitro and 
in vivo which then led to bone destruction. Interestingly, 
MDSCs derived from myeloma-bearing mice differentiate to 
osteoclasts with significantly higher capacity compared to 
normal mice-derived MDSCs, both in vitro and in vivo 
[102]. It should be noted that osteoclasts enhance cancer-
associated osteolytic lesions in MM. Using an immunocom­
petent mouse model of breast cancer bone metastasis, Sawant 
and colleagues demonstrated that only tumor-derived MDSCs 
can differentiate to osteoclasts and MDSC derived from other 
organs such as blood, spleen, lymph nodes, and lung are not 
involved in osteoclastogenesis process, both in vitro and 
in vivo. Moreover, this process was not observed in MDSCs 
derived from control or tumor-bearing mice without bone me­
tastasis, implying the critical role of BM-derived factors for 
differentiation of MDSCs to osteoclast [102]. In another study, 
Ramachandran et al. reported that CD11b+CD14−CD33+ im­
munosuppressive MDSCs are significantly increased in BM 
of newly diagnosedMM patients. Moreover, they investigated 
the role of MDSCs in mice injected with intravenous tumor 
cell lines derived from transgenic Bcl-xl/Myc mice (ATLN 
and DP42). Their results showed that both M-MDSC and G-
MDSC populations were increased in mice as early as 1 week 
after MM cell inoculation. Investigation of MDSCs in 
S100A9 deficient MM inoculated mice showed the decreased 
frequency of these cells in the BM which was associated with 
upregulation of antigen-specific CD8+ T cells in BM and 
spleens and was abrogated by the administration of anti­
CD8 antibody or adoptive transfer of MDSC. Moreover, 
MDSCs from MM-bearing mice exerted significantly higher 
immunosuppressive effect compared to immature myeloid 
cells from naïve mice. Authors suggested that expansion of 
MDSCs at early stages of MM plays a key role in disease 
progression [103]. It is observed that the frequency of MDSCs 
in the BM initially increases, however, then gradually reduces 
at the end stages of disease, as observed in the MM mice 
models [11]. There is other evidence which more substantiates 
this claim. De Veirman et al. reported that MDSCs accumulate 
in the BM of 5TMM mice during MM progression in early 
stages of disease, while they were increased in circulation at 
later stages. Moreover, in vivo depletion of MDSCs via anti­
GR1 antibodies and 5-fluorouracil led to tumor attenuation in 
5TMM mice [104]. It seems that cell to cell communications 
between malignant cells and myeloid progenitor cells may 
lead to initial upregulation of MDSCs in the BM. It is sug­
gested that MM cells induce MDSCs and enhance their sur­
vival in part through secretion of soluble factors that increase 
the expression of Mcl-1 in MDSCs [104]. 
It is reported that the frequency of CD14+ HLA-DR−/low 
M-MDSCs is increased in the peripheral blood of patients 
with MM at diagnosis stage [105]. On the other hand, there 
is evidence which indicates the intact frequency of M-MDSC 
and increased CD11b+CD14−CD33+CD15+ [103] or  
CD11b+CD14−CD33+CD15+HLA-DRlow [106] G-MDSCs  
in the BM and peripheral blood of MM patients. There are 
similar results regarding the increased frequency of G-
MDSCs in the peripheral blood of MM patients with progres­
sive disease [107]. Franssen et al. have also been reported that 
the frequencies of highly suppressive CD14+ MDSCs, CD14−
MDSCs, and Treg cells are increased in the blood of MM 
patients [108]. These discrepancies may be in part due to 
various sample sizes and different therapeutic drugs of MM 
patients. It should be noted that both M-MDSC and G-MDSC 
isolated fromBM ofMMpatients could inhibit Tcells in vitro, 
while immature myeloid cells of normal individuals had not 
immunosuppressive properties [103]. Although it is reported 
that MDSCs help thegrowth of MM cells in part through sup­
pression of T cells [106], little is known regarding the mech­
anisms by which MDSCs accumulate in MM patients. It is 
suggested that MM cells or other BM-derived stromal cells 
may secrete various MDSC-promoting factors such as IL-6, 
GM-CSF, VEGF, and IL-1β, which help to development of 
MDSCs [109, 110]. These cytokines are also involved in sev­
eral adaptive and innate immune responses [111–113]. 
It is recently demonstrated that G-MDSCs can significantly 
suppress both CD8+ T and NKT cells which was associated 
with MM growth. Moreover, MM cells could induce MDSCs 
from peripheral blood mononuclear cells of normal subjects, 
implying a reciprocal interaction between MDSCs, MM cells, 
and immune effector cells. Furthermore, inhibition of MDSCs 
using lenalidomide and bortezomib immunomodulatory drugs 
led to disease attenuation in MM patients [ 106].  De 
Keersmaecker and coworkers have recently reported that 
CD14+HLA-DRlow/− M-MDSCs constitute about 3.5 % of 
PBMCs in MM patients. Surprisingly, they showed that both 
the CD11b+CD14+HLADRlow/− and CD11b+CD14+HLA-
DRhigh cells can exert immunosuppressive effects leading to 
decreased Tcell proliferation and cytokine production, in vitro 
[114]. A latter subpopulation was expected to act as antigen 
presenting cell, thereby activating T cells similar to previous 
report; however, it is not clear how these HLA-DRhigh cells 
suppressed T cells. Like the previous report, addition of 
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immunomudulatory drugs to in vitro coculture of MDSC/T 
cells led to decreased T cell proliferation, but did not affect 
cytokine production [114]. Other investigators reported that 
G-MDSCs are increased in the blood of progressive MM pa­
tients and can induce Treg cells, in vitro. They showed that 
both normal- and MM patients-derived MDSCs can inhibit T 
cell proliferation in a dose-dependent manner. Moreover, ad­
ministration of G-CSF to MM patients led to increased fre-
quency of MDSCs in the peripheral blood [107]. It is reported 
that administration of lenalidomide to MM patients increases 
the frequency of both T cells and MDSCs. Moreover, 
CD14+CD15+ MDSCs could suppress the proliferation of 
both CD4+ and CD8+ T cells, in vitro. There was a significant 
correlation between the frequencies of T cells, Treg, and 
MDSCs in lenalidomide-treated patients, which implies that 
lenalidomide enhances both the activating and inhibitory com­
ponents of the immune system [115]. Tadalafil, a phosphodi­
esterase 5 (PDE5) inhibitor, is another MDSC-targeting drug 
which its administration to end-stage relapsed/refractory MM 
patients decreased MDSC function and enhanced durable 
anti-myeloma immune response [116]. Wang and colleagues 
have also been reported that the frequency of M-MDSCs is 
increased and correlated with disease progression in newly 
diagnosed and relapsed MM patients compared to MM pa­
tients in remission and normal subjects. Moreover, patient­
derived plasma or MM cells could induce M-MDSCs, 
in vitro. Treatment of MM patients with bortezomib (protea­
some inhibitory) was associated with downregulation of 
MDSCs [117]. Furthermore, it has recently demonstrated that 
the expression of PD-L1 on MDSCs is higher than antigen-
presenting cells in MM patients. Moreover, blockade of PD1/ 
PD-L1 pathway prevented MDSC-induced MM cell growth. 
Combination of lenalidomide and PD1/PD-L1-blockade led 
to further abrogation of MDSC-mediated immune suppression 
[118]. 
It seems that the frequency of MDSCs is increased in MM 
patients and correlates with disease progression (Table 1). 
Moreover, it is demonstrated that MDSCs initially expand in 
BM and can even differentiate to osteoclasts that induce bone 
lesions. Subsequently, MDSCs migrate to peripheral organs 
and induce systemic immunosuppression which leads to the 
faster disease progression. 
Lymphoma 
The B cell lymphomas affect B cells in the lymph nodes and 
usually involve older adults and immunecompromised indi­
viduals. B cell lymphomas include Hodgkin’s and rottenly 
non-Hodgkins lymphomas that can appear in low (non­
progressive) and high (progressive) grades [119]. 
There is  no  comprehensive  data  regarding the  
immunobiology of MDSCs in the B cell lymphomas. It is 
reported that coculture of monocytes with peripheral blood 
mononuclear cells (PBMCs) from 40 patients with B cell 
non-Hodgkin lymphoma (NHL) led to decreased proliferation 
of T lymphocytes, which was restored following monocyte 
depletion implying the suppressive effect of M-MDSCs. Al­
though the frequency of monocytes in NHL patients was in­
tact; however, the expression of HLA-DR on their monocytes 
was significantly less than normal subjects, which was asso­
ciated with immunosuppressive function and disease progres­
sion indicating the increased MDSCs in NHL patients. More­
over, it is suggested that this immunosuppression is in part 
through arginase-1 mechanism [120]. 
There is evidence regarding the increased frequency of 
circulating monocytes and MDSCs in patients with diffuse 
large B cell lymphoma (DLBCL) [121, 122], follicular lym­
phoma (FL) [120, 123], and Hodgkin lymphoma (HL) [124] 
indicating the prognostic potential of these cells in B cell 
lymphomas [125]. In a study of 99 [121] and 366 [122] treated  
DLBCL patients, it is found that the absolute number of 
monocytes is increased and can be considered as potent prog­
nostic marker. Moreover, investigation of lymphocyte/ 
monocyte ratio in 103 HL patients for about 8.9 years showed 
that this ratio can be an independent factor for predicting clin­
ical outcomes in HL [124]. Investigation of 99 [126] and 50  
[127] FL patients showed that lymphoma-associated macro­
phages can be considered as worthy prognostic biomarkers for 
prediction of survival in FL. Similarly, another study on 194 
FL patients demonstrated that  low CD68 expressing 
intratumoral macrophages predict outcome of FL patients 
[128]. In another study, absolute number of monocytes at di­
agnosis time was associated with overall survival in 355 FL 
patients [122]. Increased number of CD68+ macrophages in 
nodal biopsies of 71 NHL patients has been also observed 
which was associated with disease progression [129]. 
Increased recruitment of CD68+VEGFR-1+ macrophages 
into perivascular regions of neovessels as well as the stromal 
compartment was also correlated with aggressive disease in 42 
patients with NHL [130]. The frequency of myeloid progeni­
tor cells was also correlated with disease progression in B cell 
lymphomas [131]. As discussed above, it seems that the fre­
quencies of myeloid progenitors and monocytes may be con­
sidered as potent prognostic factor for B cell lymphomas. As 
investigated, monocytes could contain M-MDSCs and mye­
loid progenitors might differentiate to MDSCs; we may con­
clude that these studies reflect the function of MDSCs in lym­
phoma patients. However, it should be noted that MDSCs 
constitute a small fraction of monocytes or myeloid progeni­
tors, so a direct conclusion from monocytes or myeloid pro­
genitors to MDSCs may not be rational. Thus, we need to 
discuss in this field using the literatures that have directly 
investigated MDSCs in B cell lymphomas. 
Serafini and colleagues have demonstrated that MDSCs act 
as tolerogenic antigen-presenting cells (APCs) which present 
tumor-derived antigens to Treg cells and expand these cells in 
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Table 1 Studies related to the role of MDSCs in multiple myeloma 
Main claim Ref. 
1. The frequencies of immature myeloid cells and M-MDSCs are significantly increased in the BM of MM mice [101] 
2. M-MDSCs subdivide into various subsets based on Ly6C expression 
1. MDSCs accumulate in the blood, BM, and spleen over time in the MM mice [102] 
2. The tumor-induced MDSCs can differentiate into mature and functional osteoclasts 
1. MDSCs are significantly increased in the BM of newly diagnosed MM patients [103] 
2. Both M-MDSCs and G-MDSCs are increased in mice as early as 1 week after MM cell inoculation
The frequency of MDSCs in the BM of MM mice initially increases, however, then gradually reduces at end stages of disease [11, 104]
M-MDSCs are increased in the peripheral blood of patients with MM at diagnosis stage [105]
The frequency of M-MDSCs is intact, while G-MDSCs are increased in the BM and peripheral blood of MM patients [103]
The frequency of G-MDSCs is increased in the BM and peripheral blood of MM patients [106, 107]
The frequencies of highly suppressive CD14+ MDSCs, CD14− MDSCs are increased in the blood of MM patients [108]
1. G-MDSCs suppress both CD8+ T and NKT cells which is associated with MM growth [106] 
2. MM cells induce MDSCs from peripheral blood mononuclear cells of normal subjects 
1. M-MDSCs constitute about 3.5 % of PBMCs in MM patients [114] 
2. Both CD11b+CD14+HLADRlow/− cells and CD11b+CD14+HLA-DRhigh cells can exert immunosuppressive effects 
G-MDSCs are increased in blood of progressive MM patients and can induce Treg cells [107] 
Administration of lenalidomide to MM patients increases the frequency of MDSCs [115] 
Administration of tadalafil to end-stage relapsed/refractory MM patients decreased MDSC function and enhanced durable anti-myeloma immune response [116] 
1. The frequency of M-MDSCs is increased and correlated with disease progression in newly diagnosed and relapsed MM patients [117] 
2. Treatment of MM patients with bortezomib (proteasome inhibitory) was associated with downregulation of MDSCs 
1. Expression of PD-L1 on MDSCs is higher than antigen presenting cells in MM patients and its blockade prevented MDSC-induced MM cell growth [118] 
2. Combination of lenalidomide and PD1/PD-L1-blockade led to further abrogation of MDSC-mediated immune suppression 
MDSC myeloid-derived suppressor cell, MM multiple myeloma, BM bone marrow, NKT natural killer T, HLA human leukocyte antigen, Treg regulatory 
T cell,  PD-L programmed death ligand 
part through arginase but not TGF-β in A20 B cell lymphoma 
model. They also showed that upregulation of IL-4Rα on 
MDSCs was associated with suppression of CD8+ but not 
CD4+ T cells. NOHA (arginase inhibitor) or sildenafil could 
inhibit Treg proliferation and tumor-induced tolerance in 
antigen-specific T cells through suppression of MDSCs both 
in vitro and in vivo [132]. Study of 91 untreated patients with 
DLBL showed a monocytosis in 17.6 % of the patient, which 
was known as an independent prognostic factor and correlated 
with worse overall survival. They also investigated the fre­
quency of M-MDSCs in peripheral blood of 23 patients and 
reported that these cells are significantly increased in these 
patients compared to normal subjects [133]. This report may 
explain the relation between monocytosis and poor prognosis 
in B cell malignancies because it seems that monocytosis is 
usually associated with expansion of M-MDSCs. 
It has been shown that CD11b+Gr1+ MDSCs persisted within 
lymphoid organs after treatment with cyclophosphamide and 
rituximab/CpG in murine B cell lymphoma expressing human 
CD20 [134]. Gustafson and coworkers have also been shown 
that while there is a positive correlation between the number of 
granulocytes and immunosuppressive CD14+HLA-DRlow/−
monocytes, no correlation exists between CD14+HLA-DRlow/−
monocytes and Lin−CD33+HLA-DR− MDSCs [135]. It is also 
demonstrated that the ameliorative effect of lenalidomide and 
fusion DNA lymphoma vaccine in pre-established syngeneic 
A20 lymphomas is associated with downregulation of circulat­
ing Treg andMDSCs in tumor-bearing but not naïve mice [136]. 
Furthermore, all circulating MDSC subsets including monocyt­
ic, granulocytic, and CD34+ population were increased in 60 
consecutive newly diagnosed HL patients and correlated with 
clinical variables at diagnosis and outcome. Although all MDSC 
subsets were increased in HL patients, a potent prognostic sig­
nificance was confined to immature CD34+ MDSCs [137]. 
Most recently, Sato et al. demonstrated that MDSCs are 
increased in NHL patients and inversely correlated with NK 
cells. Using EL4 murine lymphoma model, they showed that 
the Gr1+CD11b+Ly6GmedLy6Cmed MDSCs (non-monocytic 
and non-granulocytic) MDSCs are increased following NK 
cell depletion, indicating the regulatory effect of NK cells on 
MDSCs. It should be noted that these MDSCs secrete IL-10 
but not NO or arginase. They also showed that the increased 
frequencies of both IL-10-producing CD14+HLA-DR− and 
CD14− HLA-DR− MDSCs in NHL patients were associated 
with decreased NK cells in peripheral blood [138]. 
As discussed above, it seems that the frequencies of mye­
loid progenitors, immature myeloid cells, monocytes, and 
MDSCs are increased in various B cell lymphomas and cor­
relate with disease prognosis (Table 2). Moreover, administra­
tion of various therapeutic drugs was associated with down-
regulation of MDSCs implying the lymphoma-promoting 
function of these cells. 
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Table 2 Studies related to the role of MDSCs in B cell-derived lymphomas and leukemia 
Main claim Ref. 
MDSCs induce Treg cells and expand these cells in A20 B cell lymphoma model [132] 
M-MDSCs are significantly increased in the patients with DLBCL compared to normal subjects [133] 
MDSCs persisted within lymphoid organs after treatment with cyclophosphamide and rituximab/CpG in murine [134] 
B cell lymphoma expressing human CD20 
While there is a positive correlation between the number of granulocytes and immunosuppressive M-MDSCs, [135] 
no correlation exists between M-MDSCs and Lin−CD33+HLA-DR− MDSCs 
Lenalidomide and fusion DNA lymphoma vaccine attenuate pre-established syngeneic A20 lymphomas in pat [136] 
through downregulation of circulating Treg and MDSCs 
All circulating MDSC subsets including monocytic, granulocytic, and CD34+ population are increased in newly [137] 
diagnosed HL patients 
MDSCs are increased in NHL patients and inversely correlated with NK cells [138] 
1. The frequency of MDSCs is increased in untreated CLL patients [80] 
2. MDSCs suppress T cell activation and induce Treg cells 
3. CLL cells induce IDOhigh MDSCs from monocytes derived from healthy subjects 
The frequency of M-MDSCs is increased in CLL patients, which was correlated with disease progression [139] 
MDSC myeloid-derived suppressor cell, DLBCL diffuse large B cell lymphoma, HLA human leukocyte antigen, Treg regulatory T cell, HL Hodgkin 
lymphoma, NHL non- Hodgkin lymphoma, NK natural killer, CLL chronic lymphocytic leukemia, IDO indoleamine 2,3-dioxygenase 
Leukemia B cells, which are not fully developed and are characterized as 
blasts or leukemia cells. Unfortunately, little is known regard-
B cell-derived Leukemia is a group of B cell cancers that ing the immunobiology of MDSCs in patients with B cell 
usually begins in the BM and leads to expansion of abnormal leukemia. Recently, Jitschin et al. reported that the frequency 
Fig. 2 Malignant B cells produce soluble factors that improve the 
development and activation of MDSCs. On the other hand, MDSCs 
induce immunosuppressive microenvironment in which malignant cells 
can freely expand. MDSCs can induce Treg cells through secretion of 
cytokines such as IL-10 and TGF-β. Moreover, MDSCs promote the 
differentiation of Th2 and anti-inflammatory (M2) macrophages 
through IL-10.  Treg,  Th2 ,  and  M2  macrophages  supply  
immunosuppressive microenvironment, which help to expansion of 
malignant cells. On the other hand, MDSCs directly inhibit anti-tumor 
responses exerted by CTLs, NK, and Th cells via inhibitory cytokines, 
arginase, and iNOS. VEGF vascular endothelial growth factor, STAT 
signal transducer and activator of transcription, MDSC myeloid-derived 
suppressor cell, TGF-β1 transforming growth factor beta, CTL cytotoxic 
T lymphocytes,  FOX3 forkhead box 3, IL interleukin, CD4 cluster of 
differentiation, Tregs regulatory T cells, NK natural killer cells, NKG2D 
natural killer group 2D, IFN-γ interferon gamma, Th2 T helper 2  
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of CD1+HLA-DRlow MDSCs is increased in untreated CLL 
patients compared to normal subjects. They showed that 
MDSCs could suppress Tcell activation and induce Treg cells, 
in vitro, which was in part through overexpression of IDO. 
Interestingly, CLL cells could induce IDOhigh MDSCs from 
monocytes derived from healthy subjects, in vitro [80]. An­
other group has recently reported that the frequency of 
CD14+HLA-DRlow/−MDSCs is increased in 49 CLL patients, 
which was associated with disease progression and poor prog-
nosis [139]. Thus, it seems that MDSCs are increased in B cell 
leukemia patients and their frequency is in correlation with 
MDSCs which may be in part due to stimulatory effects of 
leukemic B cells on expansion ofMDSCs (Table 2). However, 
we need further investigations to know how leukemic cells 
induce MDSCs. 
Impact of MDSCs on the molecular mechanisms 
responsible for B cell malignancies 
Little is known regarding the B cell molecular mechanisms 
affected by MDSCs during tumorigenesis process. B cells in 
different malignancies are in different maturation stages im­
plying the regulatory mechanism(s) which led to maturation 
stop and malignancy. Using cocultures of BM-derived cells 
with OP9 stromal cells, Kennedy and colleagues have recently 
reported that adipocyte-conditioned medium enhances the 
generation of CD11b+Gr1+ MDSCs, which can block B cell 
development, in vitro. As addition of anti-IL-1 antibodies re­
stored B lymphopoiesis, they implied that MDSCs exert their 
inhibitory effect in part through secretion of IL-1 cytokine. 
Moreover, they demonstrated that arginase and iNOS en­
zymes did not affect B cell lymphopoiesis process [140]. An­
other study has indicated that mouse M-MDSCs inhibit B cell 
responses against LP-BM5 retrovirus infection through 
iNOS/NO and the MDSC-expressed negative-checkpoint reg­
ulator VISTA. It should be noted that they did not investigate 
the role of arginase or soluble factors in inhibition of B cell 
responses [141]. Other investigators showed that M-MDSCs 
from CIA mice inhibit autologous B cell proliferation and 
antibody production through the production of NO and 
PGE2 and require cell-cell contact [141]. It is also reported 
that MDSCs can suppress B cell proliferation and antibody 
production through PGE2, iNOS, and arginase in both in vitro 
and in vivo [142]. Similarly, it is demonstrated that MDSCs 
suppress B cell expansion in mice through iNOS mechanism 
but not through arginase activity, PD-1-PD-L1 expression, 
and IL-10 production [143]. All of the above discussed studies 
were related to the effects of MDSCs on B cells in non­
tumoral condition, and little is known regarding the effect of 
MDSCs on malignant B cells. In the majority of studies, it is 
suggested that MDSCs do not play an important role in the 
initial transformation of B cells to malignant lymphocytes. 
Moreover, it seems that these are malignant B cells which 
provide a stimulatory condition for induction and expansion 
of MDSCs. Subsequently, activated MDSCs help to overex­
pansion of malignant cells. Thus, it seems that malignant B 
cells help to the development of MDSCs, and in turn, MDSCs 
support upregulation of malignant B cells. Several issues 
should be investigated regarding the stimulatory effects of 
MDSCs on B cell transformation and tumorigenesis process. 
For example, there is no comprehensive data regarding the 
cell contact-dependent mechanisms which may provoke ma­
lignant B cell expansion. Moreover, MDSCs can secrete sev­
eral cytokines, such as IL-10 which may play an important 
role in the upregulation of malignant B cells, which are not 
studied until now. It is generally stated that MDSCs provide an 
immunosuppressive microenvironment (for example, through 
induction of Treg cells) in which malignant B cells can freely 
expand; however, it is unknown whether MDSCs can also 
affect B cell malignancies through IgA class switching 
mechanism. 
Conclusion 
MDSCs promote expansion of malignant lymphocytes in B 
cell malignancies in part through suppression of anti-tumor 
responses. Unfortunately, we have no comprehensive and jus­
tified reports about the immunobiology of MDSCs, their sub­
sets characteristics, and functions in different B cell malignan­
cies, particularly leukemia. It seems that there is a reciprocal 
relation loop between malignant B cells and immature mye­
loid cells in which malignant B cells induce and recruit 
MDSCs and MDSCs secrete tumor-expanding factors 
(Fig. 2); however, little is known regarding the detail of this 
relation and this issue deserves further investigations. Identi­
fication of effector factors behind the this relation loop and 
targeting them in combination with other potent immunother­
apeutic approaches may be considered as novel promising 
approach for treatment of B cell malignancies. 
Acknowledgments None. 
Conflicts of interest None 
References 
1. Bachireddy P, Burkhardt UE, RajasagiM,Wu CJ. Haematological 
malignancies: at the forefront of immunotherapeutic innovation. 
Nat Rev Cancer. 2015;15:201–15. 
2. Wu AA, Drake V, Huang H-S, Chiu S, Zheng L. Reprogramming 
the tumor microenvironment: tumor-induced immunosuppressive 
factors paralyzing t cells. OncoImmunology 2015:00–00. 
3. Bahrami B, Mohammadnia-Afrouzi M, Bakhshaei P, Yazdani Y, 
Ghalamfarsa G, Yousefi M, et al. Folate-conjugated nanoparticles 
as a potent therapeutic approach in targeted cancer therapy. Tumor 
Biol 2015:1–16 
7349 Tumor Biol. (2015) 36:7339–7353 
4. Jadidi-Niaragh F, Yousefi M, Memarian A, Hojjat-Farsangi M, 
Khoshnoodi J, Razavi SM, et al. Increased frequency of CD8+ 
and CD4+ regulatory t cells in chronic lymphocytic leukemia: 
association with disease progression. Cancer Investig. 2013;31: 
121–31. 
5. Ghalamfarsa G, Hadinia A, Yousefi M, Jadidi-Niaragh F. The role 
of natural killer T cells in B cell malignancies. Tumor Biol. 
2013;34:1349–60. 
6. Raggi C, Mousa H, Correnti M, Sica A, Invernizzi P. Cancer stem 
cells and tumor-associated macrophages: a roadmap for 
multitargeting strategies. Oncogene 2015 
7. Vetro C, Romano A, Ancora F, Coppolino F, BrundoMV, Raccuia 
SA, et al. Clinical impact of the immunome in lymphoid malig­
nancies: the role of myeloid-derived suppressor cells. Frontiers in 
Oncology. 2015;5:104. 
8. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor 
cells in human diseases. Int Immunopharmacol. 2011;11:802–7. 
9. YoungMR, NewbyM,Wepsic HT. Hematopoiesis and suppressor 
bone marrow cells in mice bearing large metastatic lewis lung 
carcinoma tumors. Cancer Res. 1987;47:100–5. 
10. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived 
suppressor cells—an overview of combat strategies to increase 
immunotherapy efficacy. OncoImmunology. 2015;4, e954829. 
11. De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De 
Bruyne E, Menu E, et al. Myeloid-derived suppressor cells as 
therapeutic target in hematological malignancies. Frontiers in 
Oncology. 2014;4:349. 
12. Younos IH, Abe F, Talmadge JE. Myeloid-derived suppressor 
cells: their role in the pathophysiology of hematologic malignan­
cies and potential as therapeutic targets. Leuk Lymphoma. 
2014;21:1–13. 
13. Maenhout SK, Thielemans K, Aerts JL. Location, location, loca­
tion: functional and phenotypic heterogeneity between tumor-
infiltrating and non-infiltrating myeloid-derived suppressor cells. 
OncoImmunology. 2014;3, e956579. 
14. Katoh H, Watanabe M. Myeloid-derived suppressor cells and 
therapeutic strategies in cancer. Mediat Inflamm. 2015;501: 
159269. 
15. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as reg­
ulators of the immune system. Nat Rev Immunol. 2009;9:162–74. 
16. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo 
MP, et al. Tumors induce a subset of inflammatory monocytes 
with immunosuppressive activity on CD8+ T cells. J Clin 
Investig. 2006;116:2777. 
17. Schouppe E, Van Overmeire E, Laoui D, Keirsse J, Van 
Ginderachter JA. Modulation of CD8+ T-cell activation events 
by monocytic and granulocytic myeloid-derived suppressor cells. 
Immunobiology. 2013;218:1385–91. 
18. Ma C, Kapanadze T, Gamrekelashvili J, Manns MP, Korangy F, 
Greten TF. Anti-Gr-1 antibody depletion fails to eliminate hepatic 
myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc 
Biol. 2012;92:1199–206. 
19. Fleming T, Fleming M, Malek T. Selective expression of Ly-6G 
on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb 
to granulocyte-differentiation antigen (Gr-1) detects members of 
the Ly-6 family. J Immunol. 1993;151:2399–408. 
20. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, 
Mandruzzato S, et al. Myeloid-derived suppressor cell heteroge­
neity and subset definition. Curr Opin Immunol. 2010;22:238–44. 
21. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of 
myeloid-derived suppressor cells in tumor-bearing mice. J 
Immunol. 2008;181:5791–802. 
22. Dolen Y, Gunaydin G, Esendagli G, Guc D. Granulocytic subset 
of myeloid derived suppressor cells in rats with mammary carci­
noma. Cell Immunol. 2015;295:29–35. 
23. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, 
et al. Complexity and challenges in defining myeloid-derived sup­
pressor cells. Cytometry B Clin Cytom. 2015;88:77–91. 
24. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, 
Mesa C, et al. Hierarchy of immunosuppressive strength among 
myeloid-derived suppressor cell subsets is determined by GM­
CSF. Eur J Immunol. 2010;40:22–35. 
25. Youn JI, Gabrilovich DI. The biology ofmyeloid-derived suppres­
sor cells: the blessing and the curse of morphological and func­
tional heterogeneity. Eur J Immunol. 2010;40:2969–75. 
26. Monu N, Frey AB. Suppression of proximal T cell receptor sig­
naling and lytic function in CD8+ tumor-infiltrating T cells. 
Cancer Res. 2007;67:11447–54. 
27. Trikha P, Carson WE. Signaling pathways involved in MDSC 
regulation. Biochimica et Biophysica Acta (BBA)-Reviews on 
Cancer. 2014;1846:55–65. 
28. Saleem SJ, Conrad DH. Hematopoietic cytokine-induced tran­
scriptional regulation and notch signaling as modulators of 
MDSC expansion. Int Immunopharmacol. 2011;11:808–15. 
29. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, 
Kalinski P. PGE2-driven induction and maintenance of cancer-
associated myeloid-derived suppressor cells. Immunol Investig. 
2012;41:635–57. 
30. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta 
J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is in­
duced by COX-2 in lung carcinoma. The Journal of experimental 
medicine. 2005;202:931–9. 
31. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. 
Prostaglandin E2 promotes tumor progression by inducing 
myeloid-derived suppressor cells. Cancer Res. 2007;67:4507–13. 
32. Donkor MK, Lahue E, Hoke TA, Shafer LR, Coskun U, Solheim 
JC, et al. Mammary tumor heterogeneity in the expansion of 
myeloid-derived suppressor cells. Int Immunopharmacol. 
2009;9:937–48. 
33. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet 
MJ. A CSF-1 receptor kinase inhibitor targets effector func­
tions and inhibits pro-inflammatory cytokine production 
from murine macrophage populations. FASEB J. 2006;20: 
1921–3. 
34. Zhou Z, French DL, Ma G, Eisenstein S, Chen Y, Divino CM, 
et al. Development and function of myeloid-derived suppressor 
cells generated from mouse embryonic and hematopoietic stem 
cells. Stem Cells. 2010;28:620–32. 
35. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado 
AX, Moughon DL, et al. Targeting distinct tumor-infiltrating my­
eloid cells by inhibiting CSF-1 receptor: combating tumor evasion 
of antiangiogenic therapy. Blood. 2010;115:1461–71. 
36. Martins A, Han J, Kim SO. The multifaceted effects of granulo­
cyte colony-stimulating factor in immunomodulation and poten­
tial roles in intestinal immune homeostasis. IUBMB life. 2010;62: 
611–7. 
37. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. 
High-dose granulocyte-macrophage colony-stimulating factor-
producing vaccines impair the immune response through the re­
cruitment of myeloid suppressor cells. Cancer Res. 2004;64: 
6337–43. 
38. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, 
Amankulor N, et al. Gm-CSF promotes the immunosuppressive 
activity of glioma-infiltrating myeloid cells through interleukin-4 
receptor-α. Cancer Res. 2013;73:6413–23. 
39. Bronte V, Chappell DB, Apolloni E, Cabrelle A, WangM, Hwu P, 
et al. Unopposed production of granulocyte-macrophage colony­
stimulating factor by tumors inhibits CD8+ T cell responses by 
dysregulating antigen-presenting cell maturation. J Immunol. 
1999;162:5728–37. 
7350 Tumor Biol. (2015) 36:7339–7353 
40. Abrams SI, Waight JD. Identification of a G-CSF-granulocytic 
mdsc axis that promotes tumor progression. OncoImmunology. 
2012;1:550–1. 
41. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, et al. IL-17 
promotes tumor development through the induction of tumor pro­
moting microenvironments at tumor sites and myeloid-derived 
suppressor cells. J Immunol. 2010;184:2281–8. 
42. Cai X-Y, Gommoll Jr CP, Justice L, Narula SK, Fine JS. 
Regulation of granulocyte colony-stimulating factor gene expres­
sion by interleukin-17. Immunol Lett. 1998;62:51–8. 
43. McLemore ML, Grewal S, Liu F, Archambault A, Poursine-
Laurent J, Haug J, et al. STAT-3 activation is required for normal 
G-CSF-dependent proliferation and granulocytic differentiation. 
Immunity. 2001;14:193–204. 
44. Schroeder T, Kohlhof H, Rieber N, Just U. Notch signaling in­
duces multilineage myeloid differentiation and up-regulates PU.1 
expression. J Immunol. 2003;170:5538–48. 
45. Panopoulos AD, Watowich SS. Granulocyte colony-stimulating 
factor: molecular mechanisms of action during steady state and 
‘emergency’hematopoiesis. Cytokine. 2008;42:277–88. 
46. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib 
inhibition of Stat3 induces renal cell carcinoma tumor cell apopto­
sis and reduces immunosuppressive cells. Cancer Res. 2009;69: 
2506–13. 
47. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-
CSF facilitates neoplastic growth through a granulocytic myeloid­
derived suppressor cell-dependent mechanism. PLoS One. 
2011;6, e27690. 
48. Nicholson SE, Oates AC, Harpur AG, Ziemiecki A, Wilks AF, 
Layton JE. Tyrosine kinase JAK1 is associated with the 
granulocyte-colony-stimulating factor receptor and both become 
tyrosine-phosphorylated after receptor activation. Proc Natl Acad 
Sci. 1994;91:2985–8. 
49. Huang Y, Chen X, DikovMM, Novitskiy SV, Mosse CA, Yang L, 
et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant 
hematopoiesis associated with elevated levels of VEGF. Blood. 
2007;110:624–31. 
50. Larrivée B, Pollet I, Karsan A. Activation of vascular endothelial 
growth factor receptor-2 in bone marrow leads to accumulation of 
myeloid cells: role of granulocyte-macrophage colony-stimulating 
factor. J Immunol. 2005;175:3015–24. 
51. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, 
et al. Vascular endothelial growth factor inhibits the development 
of dendritic cells and dramatically affects the differentiation of 
multiple hematopoietic lineages in vivo. Blood. 1998;92:4150– 
66. 
52. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, 
Gysemans C, Beschin A, et al. Identification of discrete tumor­
induced myeloid-derived suppressor cell subpopulations with dis­
tinct T cell-suppressive activity. Blood. 2008;111:4233–44. 
53. Zhao J, Kong HJ, Li H, Huang B, Yang M, Zhu C, et al. IRF-8/ 
interferon (IFN) consensus sequence-binding protein is involved 
in toll-like receptor (TLR) signaling and contributes to the cross­
talk between TLR and IFN-γ signaling pathways. J Biol Chem. 
2006;281:10073–80. 
54. Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, ex­
pansion and activation of myeloid-derived suppressor cells. Med 
Microbiol Immunol. 2010;199:273–81. 
55. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, 
Salup R, et al. Hyperactivation of STAT3 is involved in abnormal 
differentiation of dendritic cells in cancer. J Immunol. 2004;172: 
464–74. 
56. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, 
Gabrilovich DI. Regulation of dendritic cell differentiation and 
antitumor immune response in cancer by pharmacologic­
selective inhibition of the janus-activated kinase 2/signal 
transducers and activators of transcription 3 pathway. Cancer 
Res. 2005;65:9525–35. 
57. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-
Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic 
system elicits multicomponent antitumor immunity. Nat Med. 
2005;11:1314–21. 
58. Foell D,Wittkowski H, Vogl T, Roth J. S100 proteins expressed in 
phagocytes: a novel group of damage-associated molecular pattern 
molecules. J Leukoc Biol. 2007;81:28–37. 
59. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, 
Sotomayor E, et al. Mechanism regulating reactive oxygen spe­
cies in tumor-induced myeloid-derived suppressor cells. J 
Immunol. 2009;182:5693–701. 
60. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. 
Inhibition of dendritic cell differentiation and accumulation of 
myeloid-derived suppressor cells in cancer is regulated by 
S100A9 protein. The Journal of experimental medicine. 
2008;205:2235–49. 
61. Farren MR, Carlson LM, Lee KP. Tumor-mediated inhibition of 
dendritic cell differentiation is mediated by down regulation of 
protein kinase C beta II expression. Immunol Res. 2010;46:165– 
76. 
62. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, 
et al. Tumor-induced tolerance and immune suppression depend 
on the C/EBPβ transcription factor. Immunity. 2010;32:790–802. 
63. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Müller 
M, et al. Hepatic acute-phase proteins control innate immune re­
sponses during infection by promoting myeloid-derived suppres­
sor cell function. The Journal of experimental medicine. 
2010;207:1453–64. 
64. Kusmartsev S, Gabrilovich DI. Stat1 signaling regulates tumor-
associated macrophage-mediated T cell deletion. J Immunol. 
2005;174:4880–91. 
65. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. 
Direct and differential suppression of myeloid-derived suppressor 
cell subsets by sunitinib is compartmentally constrained. Cancer 
Res. 2010;70:3526–36. 
66. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, 
et al. IL-4-induced arginase 1 suppresses alloreactive T cells in 
tumor-bearing mice. J Immunol. 2003;170:270–8. 
67. Terabe M, Matsui S, Park J-M, Mamura M, Noben-Trauth N, 
Donaldson DD, et al. Transforming growth factor-β production 
and myeloid cells are an effector mechanism through which 
CD1D-restricted t cells block cytotoxic t lymphocyte-mediated 
tumor immunosurveillance abrogation prevents tumor recurrence. 
The Journal of experimental medicine. 2003;198:1741–52. 
68. Munera V, Popovic PJ, Bryk J, Pribis J, Caba D, Matta BM, et al. 
Stat 6-dependent induction of myeloid derived suppressor cells 
after physical injury regulates nitric oxide response to endotoxin. 
Ann Surg. 2010;251:120–6. 
69. DelanoMJ, Scumpia PO,Weinstein JS, Coco D,Nagaraj S, Kelly­
Scumpia KM, et al. MyD88-dependent expansion of an immature 
GR-1+ CD11B+ population induces T cell suppression and Th2 
polarization in sepsis. The Journal of experimental medicine. 
2007;204:1463–74. 
70. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, 
et al. Overexpression of interleukin-1β induces gastric inflamma­
tion and cancer and mobilizes myeloid-derived suppressor cells in 
mice. Cancer Cell. 2008;14:408–19. 
71. Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z, et al. 
Contribution ofMyD88 to the tumor exosome-mediated induction 
of myeloid derived suppressor cells. The American journal of 
pathology. 2010;176:2490–9. 
72. Gibb DR, Saleem SJ, Kang D-J, Subler MA, Conrad DH. 
Adam10 overexpression shifts lympho-and myelopoiesis by 
7351 Tumor Biol. (2015) 36:7339–7353 
dysregulating site 2/site 3 cleavage products of notch. J Immunol. 
2011;186:4244–52. 
73. Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y, Farajnia S. 
Natural inhibitors of PI3K/AKT signaling in breast cancer: em­
phasis on newly-discovered molecular mechanisms of action. 
Pharmacol Res. 2015;93:1–10. 
74. Chandra D, Gravekamp C. Myeloid-derived suppressor cells: cel­
lular missiles to target tumors. OncoImmunology. 2013;2, e26967. 
75. Monu NR, Frey AB. Myeloid-derived suppressor cells and anti­
tumor t cells: a complex relationship. Immunol Investig. 2012;41: 
595–613. 
76. Saio M, Radoja S, Marino M, Frey AB. Tumor-infiltrating mac­
rophages induce apoptosis in activated CD8+ T cells by a mech­
anism requiring cell contact and mediated by both the cell-
associated form of tnf and nitric oxide. J Immunol. 2001;167: 
5583–93. 
77. Gabrilovich D. Mechanisms and functional significance of 
tumour-induced dendritic-cell defects. Nat Rev Immunol. 
2004;4:941–52. 
78. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina 
G, et al. Derangement of immune responses by myeloid suppres­
sor cells. Cancer Immunol Immunother. 2004;53:64–72. 
79. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand­
Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell acti­
vation by depleting cystine and cysteine. Cancer Res. 2010;70: 
68–77. 
80. Jitschin R, Braun M, Büttner M, Dettmer-Wilde K, Bricks J, 
Berger J, et al. CLL-cells induce idohi CD14+ HLA-DRlo mye­
loid-derived suppressor cells that inhibit T-cell responses and pro­
mote tregs. Blood. 2014;124:750–60. 
81. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand­
Rosenberg S. Myeloid-derived suppressor cells down-regulate L­
selectin expression on CD4+ and CD8+ T cells. J Immunol. 
2009;183:937–44. 
82. Raber P, Ochoa AC, Rodríguez PC. Metabolism of L-arginine by 
myeloid-derived suppressor cells in cancer: mechanisms of t cell 
suppression and therapeutic perspectives. Immunol Investig. 
2012;41:614–34. 
83. Karakhanova S, Link J, Heinrich M, Shevchenko I, Yang Y, 
Hassenpflug M, et al. Characterization of myeloid leukocytes 
and soluble mediators in pancreatic cancer: importance of 
myeloid-derived suppressor cells. OncoImmunology 2015:00–00 
84. HeuversME, Muskens F, Bezemer K, LambersM, Dingemans A-
MC, Groen HJ, et al. Arginase-1 mRNA expression correlates 
with myeloid-derived suppressor cell levels in peripheral blood 
of nsclc patients. Lung Cancer. 2013;81:468–74. 
85. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, pros­
taglandins, and myeloid-derived suppressor cells in renal cell car­
cinoma. Clin Cancer Res. 2007;13:721s–6. 
86. Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, 
Ochoa JB, et al. L-arginine modulates CD3Ζ expression and t cell 
function in activated human T lymphocytes. Cell Immunol. 
2004;232:21–31. 
87. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability 
regulates T-lymphocyte cell-cycle progression. Blood. 2007;109: 
1568–73. 
88. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, 
Dalerba P, et al. Immunity to cancer: attack and escape in T lym­
phocyte–tumor cell interaction. Immunol Rev. 2002;188:97–113. 
89. Harari O, Liao JK. Inhibition of MHC II gene transcription by 
nitric oxide and antioxidants. Curr Pharm Des. 2004;10:893. 
90. Bannai S. Transport of cystine and cysteine in mammalian cells. 
Biochimica  e t  Biophysica  Acta  (BBA)-Reviews  on  
Biomembranes. 1984;779:289–306. 
91. GMÜNDER H, ECK HP, DRÖGE W. Low membrane transport 
activity for cystine in resting and mitogenically stimulated human 
lymphocyte preparations and human Tcell clones. Eur J Biochem. 
1991;201:113–7. 
92. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen­
specific inhibition of CD8+ T cell response by immature myeloid 
cells in cancer is mediated by reactive oxygen species. J Immunol. 
2004;172:989–99. 
93. Schmielau J, Finn OJ. Activated granulocytes and granulocyte­
derived hydrogen peroxide are the underlying mechanism of sup­
pression of T-cell function in advanced cancer patients. Cancer 
Res. 2001;61:4756–60. 
94. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-argi­
nine metabolism in myeloid cells controls T-lymphocyte func­
tions. Trends Immunol. 2003;24:301–5. 
95. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, 
et al. Altered recognition of antigen is a mechanism of CD8+Tcell 
tolerance in cancer. Nat Med. 2007;13:828–35. 
96. Nagaraj S, Schrum AG, Cho H-I, Celis E, Gabrilovich DI. 
Mechanism of T cell tolerance induced by myeloid-derived sup­
pressor cells. J Immunol. 2010;184:3106–16. 
97. Jayaraman P, Alfarano MG, Svider PF, Parikh F, Lu G, Kidwai S, 
et al. iNOS expression in CD4+ T cells limits treg induction by 
repressing TGFβ1: combined inos inhibition and Treg depletion 
unmask endogenous antitumor immunity. Clin Cancer Res. 
2014;20:6439–51. 
98. Li Q, Pan P-Y, Gu P, Xu D, Chen S-H. Role of immature myeloid 
Gr-1+ cells in the development of antitumor immunity. Cancer 
Res. 2004;64:1130–9. 
99. Mimura N, Hideshima T, Anderson KC. Novel therapeutic strate­
gies for multiple myeloma. Experimental Hematology 2015 
100. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. 
The 5TMM series: a useful in vivo mouse model of human mul­
tiple myeloma. Hematol J. 2000;1:351–6. 
101. Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, 
Menu E, De Baetselier P, et al. Multiple myeloma induces the 
immunosuppressive capacity of distinct myeloid-derived suppres­
sor cell subpopulations in the bone marrow. Leukemia. 2012;26: 
2424–8. 
102. Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as a 
novel target for the control of osteolytic bone disease.  
OncoImmunology. 2013;2, e24064. 
103. Ramachandran IR,Martner A, Pisklakova A, Condamine T, Chase 
T, Vogl T, et al. Myeloid-derived suppressor cells regulate growth 
of multiple myeloma by inhibiting T cells in bone marrow. J 
Immunol. 2013;190:3815–23. 
104. De Veirman K, Van Ginderachter J, Lub S, De Beule N, 
Thielemans K, Bautmans I, et al. Multiple myeloma induces 
Mcl-1 expression and survival of myeloid-derived suppressor 
cells. Oncotarget. 2015;6:10532–47. 
105. Brimnes MK, Vangsted AJ, Knudsen L, Gimsing P, Gang A, 
Johnsen HE, et al. Increased level of both CD4+ FOXP3+ regu­
latory T cells and CD14+ HLA− DR−/low myeloid-derived sup­
pressor cells and decreased level of dendritic cells in patients with 
multiple myeloma. Scand J Immunol. 2010;72:540–7. 
106. Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, 
Laubach J, et al. Tumor-promoting immune-suppressive myeloid­
derived suppressor cells in the multiple myeloma microenviron­
ment in humans. Blood. 2013;121:2975–87. 
107. Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland 
N, et al. Myeloid derived suppressor cells are numerically, func­
tionally and phenotypically different in patients with multiple my­
eloma. Leuk Lymphoma. 2014;55:2893–900. 
108. Franssen L, van de Donk N, Emmelot M, Roeven M, Schaap N, 
Dolstra H, et al. The impact of circulating suppressor cells in 
multiple myeloma patients on clinical outcome of dlis. Bone 
Marrow Transplantation 2015 
7352 Tumor Biol. (2015) 36:7339–7353 
109. Zhang X-G, Bataille R, Jourdan M, Saeland S, Banchereau J, 
Mannoni P, et al. Granulocyte-macrophage colony-stimulating 
factor synergizes with interleukin-6 in supporting the proliferation 
of human myeloma cells [see comments]. Blood. 1990;76:2599– 
605. 
110. Alexandrakis M, Passam F, Sfiridaki A, Pappa C, Moschandrea J, 
Kandidakis E, et al. Serum levels of leptin in multiple myeloma 
patients and its relation to angiogenic and inflammatory cytokines. 
The International journal of biological markers. 2003;19:52–7. 
111. Yazdani Y, Sadeghi H, Alimohammadian M, Andalib A, Moazen 
F, Rezaei A. Expression of an innate immune element (mouse 
hepcidin-1) in baculovirus expression system and the comparison 
of its function with synthetic human hepcidin-25. Iranian journal 
of pharmaceutical research: IJPR. 2011;10:559. 
112. Yazdani Y, Keyhanvar N, Kalhor HR, Rezaei A. Functional anal­
yses of recombinant mouse hepcidin-1 in cell culture and animal 
model. Biotechnol Lett. 2013;35:1191–7. 
113. Javaheri-Kermani M, Farazmandfar T, Ajami A, Yazdani Y. 
Impact of hepcidin antimicrobial peptide on iron overload in tu­
berculosis patients. Scand J Infect Dis. 2014;46:693–6. 
114. De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman 
C, Aerts JL, et al. Immunomodulatory drugs improve the immune 
environment for dendritic cell-based immunotherapy in multiple 
myeloma patients after autologous stem cell transplantation. 
Cancer Immunol Immunother. 2014;63:1023–36. 
115. Busch A, Zeh D, Janzen V, Mügge LO,Wolf D, Fingerhut L, et al. 
Treatment with lenalidomide induces immunoactivating and 
counter-regulatory immunosuppressive changes in myeloma pa­
tients. Clinical & Experimental Immunology. 2014;177:439–53. 
116. Noonan KA, Ghosh N, Rudraraju L, Bui M, Borrello I. Targeting 
immune suppression with pde-5 inhibition in end stage multiple 
myeloma: a case study. Cancer Immunology Research 2014: 
canimm. 0213.2013 
117. Wang Z, Zhang L, Wang H, Xiong S, Li Y, Tao Q, et al. Tumor­
induced CD14+ HLA-DR−/low myeloid-derived suppressor cells 
correlate with tumor progression and outcome of therapy in mul­
tiple myeloma patients. Cancer Immunol Immunother. 2015;64: 
389–99. 
118. Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, 
Anderson JE, et al. Lenalidomide enhances immune checkpoint 
blockade induced immune response in multiple myeloma. 
Clinical Cancer Research 2015:clincanres. 0200.2015 
119. Mehta-ShahN, Younes A. Novel targeted therapies in diffuse large 
B-cell lymphoma: seminars in hematology. Elsevier. 2015;52: 
126–37. 
120. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz 
AB. Immunosuppressive CD14+ HLA-DRLOW/−monocytes in B­
cell non-Hodgkin lymphoma. Blood. 2011;117:872–81. 
121. Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, 
MaconW, et al. Absolute monocyte/lymphocyte count prognostic 
score is independent of immunohistochemically determined cell 
of origin in predicting survival in diffuse large B-cell lymphoma. 
Leuk Lymphoma. 2012;53:2159–65. 
122. Wilcox R, Ristow K, Habermann T, Inwards D, Micallef I, 
Johnston P, et al. The absolute monocyte and lymphocyte prog­
nostic score predicts survival and identifies high-risk patients in 
diffuse large-B-cell lymphoma. Leukemia. 2011;25:1502–9. 
123. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, 
Johnston PB, et al. The absolute monocyte count is associated with 
overall survival in patients newly diagnosed with follicular lym­
phoma. Leuk Lymphoma. 2012;53:575–80. 
124. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, 
Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio 
at diagnosis and survival in nodular lymphocyte-predominant 
Hodgkin lymphoma. Br J Haematol. 2012;157:321–30. 
125. Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor 
cells—their role in haemato-oncological malignancies and other 
cancers and possible implications for therapy. Br J Haematol. 
2011;153:557–67. 
126. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, 
Gill K, et al. Analysis of multiple biomarkers shows that 
lymphoma-associated macrophage (LAM) content is an indepen­
dent predictor of survival in follicular lymphoma (FL). Blood. 
2005;106:2169–74. 
127. Andjelic B, Mihaljevic B, Todorovic M, Bila J, Jakovic L, 
Jovanovic MP. The number of lymphoma-associated macro­
phages in tumor tissue is an independent prognostic factor in 
patients with follicular lymphoma. Appl Immunohistochem Mol 
Morphol. 2012;20:41–6. 
128. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, 
Morchhauser F, et al. High numbers of tumor-associated macro­
phages have an adverse prognostic value that can be circumvented 
by rituximab in patients with follicular lymphoma enrolled onto 
the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26: 
440–6. 
129. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo 
F, et al. Angiogenesis extent and macrophage density increase 
simultaneously with pathological progression in B-cell non-
Hodgkin’s lymphomas. Br J Cancer. 1999;79:965. 
130. Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, ColemanM, 
et al. Magnitude of stromal hemangiogenesis correlates with his­
tologic subtype of non-Hodgkin’s lymphoma. Clin Cancer Res. 
2006;12:5622–31. 
131. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell’Agnola C, 
Gobbi A, et al. Kinetics and viability of circulating endothelial 
cells as surrogate angiogenesis marker in an animal model of hu­
man lymphoma. Cancer Res. 2001;61:4341–4. 
132. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid­
derived suppressor cells promote cross-tolerance in B-cell 
lymphoma by expanding regulatory T cells. Cancer Res. 
2008;68:5439–49. 
133. Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at 
diagnosis correlates with survival in diffuse large B-cell lympho­
ma—possible link with monocytic myeloid-derived suppressor 
cells. Hematol Oncol. 2013;31:65–71. 
134. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van 
Rooijen N, et al. Combination of cyclophosphamide, rituximab, 
and intratumoral cpg oligodeoxynucleotide successfully eradicates 
established B cell lymphoma. J Immunother. 2012;35:534–43. 
135. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League 
SC, et al. Immune monitoring using the predictive power of im­
mune profiles. J ImmunoTher Cancer. 2013;1:7–18. 
136. Sakamaki I, Kwak L, Cha S, Yi Q, Lerman B, Chen J, et al. 
Lenalidomide enhances the protective effect of a therapeutic vac­
cine and reverses immune suppression in mice bearing established 
lymphomas. Leukemia. 2014;28:329–37. 
137. Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera 
A, et al. Circulating myeloid-derived suppressor cells correlate 
with clinical outcome in Hodgkin lymphoma patients treated up­
front with a risk-adapted strategy. Br J Haematol. 2015;168:689– 
700. 
138. Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, 
et al. Characterization of the myeloid-derived suppressor cell sub­
set regulated  by NK cel ls  in malignant  lymphoma.  
OncoImmunology. 2015;4, e995541. 
139. Liu J, Zhou Y, Huang Q, Qiu L. CD14+ HLA-DRLOW/− expres­
sion: a novel prognostic factor in chronic lymphocytic leukemia. 
Oncology letters. 2015;9:1167–72. 
140. Kennedy DE, Knight KL. Inhibition of b lymphopoiesis by adi­
pocytes and il-1–producing myeloid-derived suppressor cells. J 
Immunol 2015:1500957 
7353 Tumor Biol. (2015) 36:7339–7353 
141. Green KA,Wang L, Noelle RJ, GreenWR. Selective involvement 
of the checkpoint regulator vista in suppression of b-cell, but not 
T-cell, responsiveness by monocytic myeloid derived suppressor 
cells from mice infected by an immunodeficiency-causing retrovi­
rus. J Virol. 2015;JVI:00888–15. 
142. Li Y, Tu Z, Qian S, Fung JJ, Markowitz SD, Kusner LL, et al. 
Myeloid-derived suppressor cells as a potential therapy for 
experimental autoimmune myasthenia gravis. J Immunol. 
2014;193:2127–34. 
143. Green KA, Cook WJ, Green WR. Myeloid-derived suppressor 
cells in murine retrovirus-induced aids inhibit T- and B-cell re­
sponses in vitro that are used to define the immunodeficiency. J 
Virol. 2013;87:2058–71. 
